×

RNS Number : 4344B

Osirium Technologies PLC

08 October 2020

 

8 October 2020

RNS REACH

 

 

Osirium Technologies plc

("Osirium" or "the Group")

 

Competitive contract win with major UK Retailer

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, is pleased to announce a contract win with a major UK high street retailer. The contract win was secured in a competitive bid against four other Privileged Access Management ("PAM") vendors and displaces an incumbent supplier, highlighting the strength of Osirium's functionality and integrated PAM platform.

 

The new client has purchased a 60-month term license for the Osirium PAM platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules. Consultancy and training from Osirium Professional Services are included in the contract.

The Osirium PAM platform has been selected after a three-month sales cycle, including a competitive Proof of Concept. Key selection criteria included ease of deployment and use, ability to connect seamlessly to a mixed Windows and Linux environment, highly flexible and resilient architecture, and ability to manage privileged account rotation on a large scale.

 

The initial priorities for the client are securing and auditing internal access to the IT infrastructure. This includes controlling access to the systems that manage devices and user accounts (including Active Directory). The client also intends to use Osirium PAM with multi-factor authentication, to integrate and automate complex and essential processes.

 

David Guyatt, Chief Executive Officer, commented: "I am delighted that Osirium has won another prestigious household name client in the retail sector. The fact that we have won against four other PAM competitors, including displacing an incumbent supplier, is further evidence of customers recognising the completeness of the Osirium proposition. The completion of the sales process in under three months is an illustration not only of increasing demand for PAM, but also of the effectiveness of our customer engagement model. We look forward to updating the market on further new contract wins and developments in due course."

 

 

For further information:

Osirium Technologies plc	Tel: +44 (0)1183 242 444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0)20 7710 7600
Fred Walsh / Richard Short
Alma (Financial PR) David Ison / Josh Royston / Kieran Breheny	Tel: +44 (0)20 3405 0205

 

Notes to Editors:

Osirium Technologies plc (AIM: OSI) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Security solutions. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

Osirium has defined and delivered what the Directors view as the next generation Privileged Access Management solution. Osirium's award-winning Privileged Task Management module further strengthens Privileged Account Security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers. Building on Osirium's Privileged Task Management module, in May 2019 Osirium launched Privileged Process Automation, providing a highly-flexible platform for automating essential IT processes to set a new benchmark in IT Process Automation. This was followed by the launch of Privileged Endpoint Manager in December 2019, bringing the total portfolio to three complementary solutions.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016. For further information please visit www.osirium.com.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAKZMGGVNFGGZM

Close

×

RNS Number : 0236B

Solid State PLC

05 October 2020

 

 

Solid State plc

("Solid State", the "Group" or the "Company")

˃$4m Optoelectronics Contract

 

 

Solid State plc (AIM: SOLI), the AIM listed manufacturer of computing, power and communications products, and value added distributor of electronic and optoelectronic components, is pleased to announce the award of a 3 year contract to supply optoelectronic modules to a leading UK instrumentation company.  The contract has been awarded to Solid State's Pacer optoelectronics business unit acquired by the Group in November 2018.

 

The customer is a long standing client of Pacer.  Approximately $1.7m will be recognised in the first year of the contract.

 

John Macmichael, Managing Director of the Value Added Distribution division, said:

"It is particularly pleasing to be announcing this contract with a longstanding customer.  It ably demonstrates the resilience of Solid State's revenues and customer relationships, whilst reinforcing the value to the Group of the recent strategic acquisition of Pacer Technologies."

 

 

For further information please contact:

 

Solid State plc	Via Walbrook PR
Gary Marsh – Chief Executive Peter James – Group Finance Director	[email protected]
Walbrook PR (Financial PR)	020 7933 8780
Tom Cooper / Paul Vann	0797 122 1972
	[email protected]

 

 

Analyst Research Reports:   For further analyst information and research see the Solid State plc website: https://solidstateplc.com/research/

 

 

Notes to Editors:

 

Solid State plc (SOLI) is a value added electronics group supplying industrial and military markets with ruggedised/durable components, assemblies and manufactured units for use in harsh environments.  The Group's mantra is – 'Trusted technology for demanding applications'.  To see an introductory video on the Group – https://youtu.be/bp4WfLCEc5Y  

 

Operating through two main divisions: Manufacturing (Steatite) and Value Added Distribution (Solid State Supplies & Pacer); the Group specialises in complex engineering challenges often requiring design-in support and component sourcing for computing, power, communications, electronic and optoelectronic products.

 

Headquartered in Redditch, Solid State employs over 200 staff across the UK with a branch office in the USA, serving specialist markets in oil & gas production, transportation, medical, construction, security, military and field maintenance. 

 

Solid State was established in 1971 and admitted to AIM in June 1996.  The Group has grown organically and by acquisition – having made 10 acquisitions since 2002.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUPGMGUUPUGMC

Close

×

RNS Number : 0211B

Mode Global Holdings PLC

05 October 2020

 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

5 October 2020

Mode Global Holdings PLC 

Admission to Trading on the London Stock Exchange and First Day of Dealings

Mode Global Holdings PLC ("Mode"), the UK-based Fintech Group, is pleased to announce that Mode's entire issued ordinary share capital  has today been admitted to the standard listing segment of the Official List of the FCA and to trading on the London Stock Exchange's Main Market for listed securities under the ticker "MODE".

 

Mode has successfully raised £7.5 million (before expenses) by way of a placing of 15 million new Ordinary Shares with institutional and other investors at a price of 50 pence per Ordinary Share (the "Placing Price"). Mode's market capitalisation at the Placing Price on admission will be £40.3 million. Peterhouse Capital Limited ("Peterhouse") is acting as Sole Broker in relation to the Admission.

 

Jonathan Rowland, Executive Chairman, commented: "The Mode offering was oversubscribed and well supported by existing investors and a range of new institutional investors. Today marks a pivotal moment for Mode, as one of the first publicly listed financial services companies with a consumer focused-digital asset offering to list on the LSE Main Market. Mode's admission is a vote of confidence in our business strategy and our mission to reduce fragmentation and inefficiencies across the banking, payments, investment and loyalty industries."

 

Enquiries   For further information please visit www.modebanking.com or contact:
(IR/PR Contact) Maitland/AMO Neil Bennett/James Isola   [email protected]	Tel: 020 7379 5151
Alfred Henry Corporate Finance Limited (Financial Adviser) Nick Michaels/Jon Isaacs	Tel: 020 3772 0021
Peterhouse Capital Limited Lucy Williams/Charles Goodfellow/Duncan Vasey	Tel: 020 7469 0930

Notes to Editors

 

Overview of Mode

 

Mode is a UK-based Fintech Group, building a modern financial services business to support an increasingly digitised economy and financial system, combining the best of banking, payments, investment, loyalty and digital assets.  Our business today comprises:

 

· Mode app – a ground-breaking digital banking app that allows users to manage their traditional and digital assets all in one place.

 

· Bitcoin Jar – one of the highest-yielding and most flexible interest-generating accounts for Bitcoin in the market (accessible through the Mode app).

 

· Business payments (WeChat and Alipay) – payment processing services for UK and European businesses to tap into the Chinese market. Mode has secured key partnerships with Tencent (WeChat) and Alipay.

 

· Business marketing services (WeChat) – marketing and social media services for UK and European businesses on one of China's most popular apps.

 

After Admission, Mode will seek to:

 

· Launch a novel payments solution powered by Open Banking that eliminates the need for cards. The new solution will aim to facilitate direct and seamless transactions in traditional and digital currency between businesses and Mode users. Mode's payment solution will not rely on the card schemes and as such will not be subject to any of their fees and/or restrictions. Furthermore, Mode's ecosystem-centric business model will seek to build a stronger consumer – business relationship, which the Directors believe will enable Mode to operate a significantly more diversified revenue model than the challenger banks, including both 'regular' Fintech revenue streams in addition to a range of more stable and high value revenue sources.

 

· Develop a loyalty and rewards engine that builds on banking, financial and payment-related insights, allowing businesses to run targeted loyalty campaigns to engage with new and existing consumers.

 

· Integrate the new payment and loyalty capabilities into the Mode app and relaunch as a next-generation super app with unique banking, payment, investment, loyalty and digital asset features, all in one.

 

· Continue to expand Mode's business client base using global payment and marketing services, connecting more UK and European businesses with a growing consumer base from China and beyond.

 

Important legal information

 

Alfred Henry Corporate Finance Limited and Peterhouse, each of which is authorised and regulated in the United Kingdom by the FCA, are acting exclusively for the Company and no one else in connection with the Company's initial public offering (the "Offer"), and will not regard any other person (whether or not a recipient of this document) as their respective clients in relation to the Offer and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the Offer or any transaction, matter, or arrangement referred to in this announcement.

 

This announcement is only addressed to and directed at specific addressees who: (A) if in member states of the European Economic Area (the "EEA"), are persons who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (as amended) ("Qualified Investors"); and (B) if in the United Kingdom, are Qualified Investors who are: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (C) are other persons to whom it may otherwise lawfully be communicated (all such persons referred to in (B) and (C) together being "Relevant Persons"). This announcement must not be acted or relied on (i) in the United Kingdom, by persons who are not Relevant Persons and (ii) in any member state of the European Economic Area by persons who are not Qualified Investors. Any investment activity to which this announcement relates (i) in the United Kingdom is available only to, and may be engaged in only with, Relevant Persons; and (ii) in any member state of the EEA is available only to, and may be engaged only with, Qualified Investors.

 

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada, Japan or South Africa. This announcement is not an offer of securities for sale into the United States, Australia, Canada, Japan or South Africa. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States. The securities may not be offered or sold in the United States, except pursuant to an applicable exemption from or in a transaction not subject to the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. No public offering of the securities referred to herein is being made in the United States.

 

Neither Alfred Henry Corporate Finance Limited, Peterhouse nor any of their respective affiliates and/or any of their or their affiliates' directors, officers, employees, advisers and/or agents accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to, the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) and/or any other information relating to the Company, Mode and/or its associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available, or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

LISEANEDELNEFEA

Close

×

Neville Registrars is delighted to welcome Mode Global Holdings plc as the newest addition to its list of client companies.

Mode Global Holdings plc is a holding company whose sole activity is to hold 100% of the shares of Mode Global Limited

Further information can be found on the Company's website: https://www.modebanking.com/

Close

×

RNS Number : 5103A

Pressure Technologies PLC

30 September 2020

 

30 September 2020

Pressure Technologies plc

("Pressure Technologies" or the "Group")

 

Major Contracts and Trading Update

 

Pressure Technologies (AIM: PRES), the specialist engineering group, today provides the following update regarding a new contract award and a milestone delay on an existing contract.

 

The Group is pleased to confirm that its Chesterfield Special Cylinders division ("CSC") has secured a significant contract, in excess of £3 million, to supply nitrogen storage solutions to EDF Energy for several UK nuclear power plants. 

 

This second major order with EDF Energy comprises ultra-large high-pressure cylinders manufactured at CSC's Sheffield facility, in a series of nitrogen storage packages for delivery through mid-FY21. The contract builds on a strong and successful relationship established with EDF Energy following the first contract, announced in October 2019.

 

In June 2020, CSC secured an order from long standing customer BAE Systems for the supply of cylinders to the UK MOD's Dreadnought class submarine programme, covering the long lead time raw material milestone for the second boat in the series.  Delayed order placement and a compressed delivery schedule are expected to result in the late receipt of material and the deferral of revenue and profit driven by this milestone from the fourth quarter of FY20 into the first quarter of FY21.

 

These major contracts with EDF Energy and BAE Systems reinforce the strong outlook for the Group's CSC division and demonstrate further progress with the Group's strategy to diversify the business into new markets, reducing a historical dependence on the oil & gas sector where the challenging trading conditions and slower than expected turnaround, compounded by the current pandemic, continue to adversely impact the performance of its Precision Machined Components division ("PMC").

 

Despite a series of proactive steps taken in PMC earlier in the year, including the closure of its loss-making Quadscot operation, divisional restructuring and cost savings, the Group expects an operating loss for the division in FY20. When combined with a lower profit anticipated in CSC, principally reflecting the expected milestone delay in the BAE Systems contract, a loss-making performance at Group level is expected for the current financial year.

 

A further trading update will be made in the second half of October, following completion of the current year end on 3 October 2020.

ENDS

 

 

 

For further information, please contact:

Pressure Technologies plc Chris Walters, Chief Executive	Tel: 0114 257 3616 [email protected]
N+1 Singer (Nomad and Broker) Mark Taylor / Carlo Spingardi	Tel: 0207 496 3000
Houston (Financial PR and Investor Relations) Kate Hoare / Anushka Mathew / Ben Robinson	Tel: 0203 701 7660

 

 

COMPANY DESCRIPTION

 

www.pressuretechnologies.com

With its head office in Sheffield, the Pressure Technologies Group was founded on its leading market position as a designer and manufacturer of high-integrity, safety-critical components and systems serving global supply chains in oil and gas, defence, industrial gases and hydrogen energy markets.

The Group has two divisions, Chesterfield Special Cylinders and Precision Machined Components.

Chesterfield Special Cylinders (CSC) –   www.chesterfieldcylinders.com  

●   Chesterfield Special Cylinders, Sheffield, includes CSC Deutschland GmbH and Chesterfield Special Cylinders Inc.

 

Precision Machined Components (PMC) –   www.pt-pmc.com

●   Precision Machined Components includes the Al-Met, Roota Engineering, Quadscot, Precision Engineers and Martract brands.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCFFFVIAIIAFII

Close

×

RNS Number : 2210A

Incanthera PLC

28 September 2020

 

 

 

28 September 2020

 

Incanthera plc

 

("Incanthera" or the "Company")

 

Sol Skin Cancer Technology

 

Successful Results of Sensitisation Study

 

Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, is pleased to announce that it has received positive data from a skin sensitisation study of its skin cancer technology Sol.

 

Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the formation of solar (actinic) keratosis and skin cancer.

 

The study, conducted by XCellR8 Ltd, has demonstrated that our Sol formulation was found to be "non-irritant" using ex-vivo human skin.

 

Formerly, studies carried out in collaboration between XCellR8 Ltd and Cutest Ltd (a CRO with particular expertise in clinical trials using topical applications) have demonstrated very good correlation between results using the methodology of this study and those obtained in clinical mildness studies.

 

Sol's "non-irritancy" was found to be comparable to baby sun protection products tested previously, with Sol scoring better those products which they would define as "very mild".

 

The Company is delighted with the results, which demonstrate that Sol is "non-irritant". The comfort and safety of human skin's reaction to the topical application of Sol is a further valuable marker of the asset and this technology.

 

These results add to the data announced on 22 September 2020, showing the exemplary penetration capabilities of Sol into the skin where it could deliver the required  bioequivalent level shown to be clinically effective.

 

Commenting on the announcement, Chairman, Tim McCarthy said:

 

"This additional positive data on Sol, greatly enhances the product's overall profile and supports our ongoing negotiations with potential commercial partners."

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

The directors of the Company take responsibility for this announcement.

 

For further enquiries:

 

Incanthera plc www.incanthera.com   Tim McCarthy, Chairman [email protected]   Simon Ward, Chief Executive Officer [email protected]   Suzanne Brocks, Head of Communications [email protected]	+44 (0) 7831 675747     +44 (0) 7747 625506     +44 (0) 7776 234600
AQSE Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis	+44 (0) 20 7213 0880
Broker: Stanford Capital Partners Ltd Patrick Claridge/John Howes/Bob Pountney	+44 (0) 20 3815 8880

 

 

Notes to Editors:

 

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

 

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

 

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

 

For more information on the Company please visit: www.incanthera.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXMZGZLMNRGGZZ

Close

×

RNS Number : 2179A

ValiRx PLC

28 September 2020

 

28 September 2020

 

("ValiRx", the "Company" or the "Group")

VAL201 Clinical Trial Update 

Headline results demonstrate VAL201 has potential to be a safe and well-tolerated drug

London, UK ValiRx (AIM:VAL) reports today that it has received headline results from the recently completed Phase 1/2 clinical trial of its lead asset VAL201, for the treatment of advanced prostate cancer, held at University College Hospital (UCLH), London.

The headline results, detailed below, provide a summary of the top-level data of safety and tolerability as well as evidence for disease impact as observed during the clinical trial.  Full data and details of from the clinical trial are expected to be received by the Company by end Q4 2020.

Disease Impact – Overall Response Rate 54.5%

Evidence for positive disease impact has been measured using PCWG2 (Prostate Cancer Working Group 2) guidelines.  These industry standard guidelines take into account both the primary tumour and metastatic tumours alongside prostate specific antigen (PSA) levels to assess whether the disease has progressed, or whether the patient has responded and halted disease progression.  These guidelines provide a more comprehensive measure of disease impact than just primary tumour imaging.

Of the 12 patients dosed with VAL201, 11 patients had sufficient PCWG2-relevant data collected across multiple cycles. 6 of these 11 have been categorised as responding throughout treatment.  That is, when the treatment with VAL201 was halted for a defined reason, whether or not the 6 standard cycles had been completed, these patients showed no disease progression by PCWG2 criteria with stable disease.

Safety and Tolerability – no Maximum Tolerated Dose declared

As the first clinical trial of VAL201, safety and tolerability data are of paramount importance. 

The headline safety and tolerability results demonstrated only one dose-limiting toxicity event occurred.  This was at a maximum dose of 8 mg/kg, with the patient having raised blood pressure (severe hypertension).   Following treatment for the raised blood pressure, the patient completed the remainder of the trial.

A Maximum Tolerated Dose has not been determined for VAL201, and all doses remain available for further testing.

No deaths were reported in patients during the clinical trial.

Further minor events listed as likely to be related to the administration of VAL201 are: Injection site disorders in 11 out of 12 patients; fatigue (5/12); dyspepsia (1/12); muscle spasm (1/12); hypertension (2/12); bradycardia (1/12).

Next Steps

During Q4 2020, the Company expects to receive the full Clinical Study Report and will use the complete data to publish the results on the National Institute of Health's (NIH) public database ClinicalTrials.gov, as well as to produce research papers for peer-reviewed publications.

The Company intends to share these results with potential industry partners to evaluate all options for further clinical development of VAL201.

Dr Suzy Dilly, Chief Executive Officer commented: "I am delighted to be able to share these exciting results today, which are an accumulation of a lot of work by the wider team, both within and external to ValiRx.  While considering these results it is important to remember that this is only the first clinical trial using VAL201, so this data has been generated using the utmost caution in sequentially dosing patients.  Nevertheless, the headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug.  With this data in hand, future studies will investigate optimal dosing strategies for VAL201 and help confirm these early indications of a positive response rate."

Professor Alan Boyd, Consultant Pharmaceutical Physician and Medical Monitor for the study commented: "Development of effective treatments with low-side effects for patients with prostate cancer who have relapsed after radiotherapy is essential and will improve the lives of patients during treatment.  I am pleased to have contributed to a project that has demonstrated such a good safety and tolerability profile while giving the first indications of a favourable effect on the patient's disease." 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

For further information please contact:

 

ValiRx plc	Tel: +44 (0) 20 7073 2628 www.valirx.com
Suzanne Dilly	[email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker	Tel: +44 (0) 20 7469 0930
Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir	Tel: +44 (0) 20 8148 3040 [email protected]

 

 

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework to enable rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the promise of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance. 

Lead candidates from our portfolio are out-licenced or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

About VAL201

VAL201 is a short peptide being studied for the treatment of prostate cancer. The peptide structure is inspired by the naturally occurring androgen receptor, and is designed to intercept and prevent the binding of the androgen receptor to SRC kinase – an enzyme implicated in cancerous cell growth pathways. By preventing the androgen-mediated activation of SRC kinase, VAL201 can potentially prevent cancerous cell proliferation (or growth) without interfering with other functions of either the androgen receptor or SRC kinase. This precision method, mimicking a natural process, proposes a high specificity of cancer treatment with a lower side effect profile. VAL201 was licensed from CRT (part of CRUK) in 2010 and developed through preclinical development into this clinical trial in patients with advanced prostate cancer. The study was held at University College Hospital (UCLH), London.

About the VAL201-001 clinical trial

The clinical trial: "A Phase I/II, Dose Escalation Study to Assess the Safety and Tolerability of VAL201 in Patients with locally Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours" opened to recruitment in December 2014 and closed in January 2020.

Patients were scheduled for treatment of a once weekly injection of VAL201 in 3 week cycles for a maximum of 6 cycles.  A total of 12 patients received at least 1 dose of VAL201.

Patients were eligible if they were: Adult men (over the age of 18) with incurable locally advanced or metastatic prostate cancer who had relapsed following radiotherapy treatment, are in 'watchful waiting' or where a policy of intermittent hormone therapy had been decided.  Patients were expected to have no or only mild symptoms relating to their prostate cancer. (ClinicalTrials.gov identifier: NCT02280317)

About Prostate Cancer

Around 48,500 men are diagnosed with prostate cancer in the UK each year[1]. In men, it is the most common cancer in the UK.  Prostate cancer is most common in older men. On average each year 35 out of 100 (35%) of new cases are in men aged 75 and over.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

Factors that could cause actual results to differ materially from those in the forward-looking statements include risks relating to unanticipated costs, liabilities or delays; failure or delays in research and development programs; the safety and efficacy of the Company's product candidates and the likelihood of clinical data to be positive and of such product candidates to be approved by the applicable regulatory authorities; unanticipated changes relating to competitive factors in the Company's industry; risks relating to the Company's capitalisation, resources and ownership structure, the availability of sufficient resources for company operations and to conduct or continue planned clinical development programs; the outcome of any legal proceedings; risks related to the ability to correctly estimate operating expenses; risks related to the ability to project future cash utilisation and reserves needed for contingent future liabilities and business operations; risks related to the changes in market prices of the Company's ordinary shares; the Company's ability to hire and retain key personnel; changes in law or regulations affecting the Company; international, national or local economic, social or political conditions that could adversely affect the Company and its business; conditions in the credit markets; risks associated with assumptions the Company makes in connection with its critical accounting estimates and other judgments.

 

Ends

 

 

---

[1] https://www.cancerresearchuk.org/about-cancer/prostate-cancer/about

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCPPUBWBUPUGMM

Close

×

RNS Number : 6544Z

Incanthera PLC

22 September 2020

 

 

 

22 September 2020

 

Incanthera plc

 

("Incanthera" or the "Company")

 

Sol Skin Cancer Technology

 

Successful Results of Permeation Study

 

Incanthera plc (AQSE: INC), the specialist oncology company focused on transforming cancer treatment, is pleased to announce successful study results for its skin cancer technology, Sol.

 

Highlights

 

Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the conversion of solar (actinic) keratoses into skin cancer.

 

· A new refined formulation of Sol demonstrates statistically significant greater dermal delivery compared with four known comparator products

· Confirmation of exceeding bioequivalence compared with oral delivery

 

The study, run by the University College of London, School of Pharmacy ("SoP"), has demonstrated that Sol affords greater permeation (delivery of the active into the skin) than comparator products.

 

The study, undertaken over the past few months, was conducted with the aim of comparing the permeability profile of a new refined formulation of Sol against a panel of four known comparator products. The comparator products comprised formulations that contain the same active ingredient over a range of concentrations, with the expectation of delivering the active through the skin for use in other general cosmetic applications.

 

The results demonstrated that Sol delivered a greater permeation of the active compared to all four assessed commercial products and that difference was statistically significant (p<0.05 at 24h).

 

In a previous study (Summer 2019), using an identical model of human skin penetration, the results demonstrated that the delivery of the active with Sol exceeded bioequivalence when compared with oral dosing of the same active. The new data from the current study confirm that this new refined formulation of Sol also exceeds bioequivalence.

 

These results have exceeded the Company's expectations, demonstrating unequivocally the efficacy of Sol's formulation in penetrating the skin barrier and reaching the deeper layers where an effective prevention of skin cancer could be achieved.

 

The Company is delighted with not only the confirmation of Sol's superior formulation technology capabilities against non-proprietary creams, but also the strength of the data received, which further enhances the data package to potential commercial partners.

 

These results follow the filing in July 2020 of a new patent protecting Sol for the prevention and treatment of solar keratoses and related cancers of the skin, which if granted, will further extend the life of the patent family protecting Sol to 2041.

 

 

Commenting on the results of the study, Chairman, Tim McCarthy said:

 

"We are delighted at demonstrating the clear efficacy advantage that Sol has when compared to other approaches at delivering the active ingredient into and across the dermal barrier.

 

The level at which the performance of this patented technology has exceeded expectations is extremely encouraging. This is an important step to enable us to move forward negotiations with potential commercial partners."

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

The directors of the Company take responsibility for this announcement.

 

For further enquiries:

 

Incanthera plc www.incanthera.com   Tim McCarthy, Chairman [email protected]   Simon Ward, Chief Executive Officer [email protected]   Suzanne Brocks, Head of Communications [email protected]	+44 (0) 7831 675747     +44 (0) 7747 625506     +44 (0) 7776 234600
Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis	+44 (0) 20 7213 0880
Broker: Stanford Capital Partners Ltd Patrick Claridge/John Howes/Bob Pountney	+44 (0) 20 3815 8880

 

 

Notes to Editors:

 

Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

 

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

 

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

 

For more information on the Company please visit: www.incanthera.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXKKDBQBBKBFCB

Close

×

Neville Registrars is delighted to welcome S-Ventures PLC as the newest addition to its list of client companies.

S-Ventures is an investment company listed on the AQUIS Exchange specialising in the natural and organic consumer sectors.

Further information can be found on the Company's website: https://s-venturesplc.com/

Close

×

RNS Number : 8226Y

N4 Pharma PLC

14 September 2020

 

14 September 2020

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Covid-19 Proof of Concept Update and move to in vivo study

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, provides an update on its Covid-19 proof of concept work utilising Nuvec® loaded with Coronavirus plasmid.

As announced on 12 August 2020, stage 2 of the proof of concept work was successfully completed with the transfection of HEK (Human Embryonic Kidney) cells of Nuvec® loaded with Coronavirus plasmid in vitro. Following the completion of stage 3 of the proof of concept work and a review of the results, the Company is continuing to explore the utility of Nuvec® with the Coronavirus plasmid and will progress to an in vivo study in due course.

 

Whilst the single intradermal injection used in the stage 3 pre (pilot) in vivo study did not result in a measurable expression of the spike protein in the target cells of the murine target, neither did the positive control. Additional exploratory studies will continue to understand the translation potency of the Coronavirus plasmid including optimisation of Nuvec® plasmid loading. With this in mind and taken together with previous positive data, the Company has decided to proceed to a full in vivo study to demonstrate the capability of Nuvec® to generate Covid-19 specific antibodies.

 

The Company is in the process of scoping the programme of studies required.

 

Nigel Theobald, Chief Executive Officer, commented: "The initial pilot work of stage 3 of the Covid-19 proof of concept work was narrow in its scope and, having reviewed the results, we have taken the decision to move to a full in vivo study to establish an immune response through the production of antibodies. In undertaking the work we aim to demonstrate Nuvec®'s capabilities both as a potential delivery technology for multiple vaccines as well as for Covid-19 specifically. I look forward to providing further updates in due course."

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

Enquiries:

 

N4 Pharma plc
Nigel Theobald, CEO	Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: +44(0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: +44(0)20 3657 0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Financial PR Graham Herring Zach Cohen	Tel: +44(0)20 3934 6630

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDKXLFFBKLXBBB

Close